CASC3 and cancer: Since its approval, the use of BTZ has been widened to treat other forms of cancers, such as relapsed mantle cell lymphoma, diffuse large B cell lymphoma, colorectal carcinoma, and thyroid carcinoma, which has effectively demonstrated that the UPS can be a suitable target for cancer therapy [7,8,9,10].